BLOOD BANKS' AUTOMATED TEST SYSTEMS FOR INFECTIOUS DISEASES SHOULD BE CONSIDERED CLASS II, BPAC RECOMMENDS; OTHER BLOOD COLLECTION DEVICES RECLASSIFIED
This article was originally published in The Gray Sheet
Automated test systems used by blood banks for infectious disease screening should be regulated as Class II devices, FDA's Blood Products Advisory Committee recommended at a June 19 meeting in Rockville, Maryland.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.